Literature DB >> 29181833

Influence of polymeric carrier on the disposition and retention of 20(R)-ginsenoside-rg3-loaded swellable microparticles in the lung.

Xiuhua Wang1, Xiao Zhang1, Linlin Fan2, Huan He2, Xiaofei Zhang1, Yuyang Zhang2, Shirui Mao3.   

Abstract

The objective of this study was to investigate the influence of differently charged biocompatible polymers, including chitosan (CS), hyaluronic acid (HA), and hydroxypropyl cellulose (HPC), on the disposition and retention of 20(R)-ginsenoside-rg3 (Rg3)-loaded swellable microparticles in the lung. A high-pressure homogenization method combined with spray drying was used to prepare Rg3-loaded microparticles. In vitro aerodynamic performance of different microparticles was characterized by the Next Generation Impactor (NGI). Retention of the swellable microparticles in the rat lung was investigated using bronchoalveolar lavage fluid method. Influence of drug loading, polymer molecular weight, and polymer charge on the properties of the swellable microparticles was investigated. It was found that drug loading had no significant influence on experimental mass median aerodynamic diameter (MMADe) and fine particle fraction (FPF). Increasing polymer molecular weight caused no remarkable change in MMADe value, but the FPF value decreased with the increase of polymer molecular weight. At the same molecular weight level, polymer structure and charge had no statistical influence on the in vitro aerodynamic properties of the microparticles and lung disposition, but it influenced the swelling and bioadhesion behavior and therefore lung retention profile. Desirable phagocytosis escapement and inhibition of A549 cell proliferation were achieved for the developed swellable microparticles. In conclusion, the lung retention of swellable microparticles can be adjusted by selecting polymeric carriers with different structure and charge.

Entities:  

Keywords:  20(R)-ginsenoside-rg3; A549 cells; Chitosan; Hyaluronic acid; Hydroxypropyl cellulose; Lung disposition and retention; Swellable microparticle

Mesh:

Substances:

Year:  2018        PMID: 29181833     DOI: 10.1007/s13346-017-0456-6

Source DB:  PubMed          Journal:  Drug Deliv Transl Res        ISSN: 2190-393X            Impact factor:   4.617


  38 in total

Review 1.  Chitosan-based drug delivery systems.

Authors:  Andreas Bernkop-Schnürch; Sarah Dünnhaupt
Journal:  Eur J Pharm Biopharm       Date:  2012-04-26       Impact factor: 5.571

2.  Pulmonary administration of a doxorubicin-conjugated dendrimer enhances drug exposure to lung metastases and improves cancer therapy.

Authors:  Lisa M Kaminskas; Victoria M McLeod; Gemma M Ryan; Brian D Kelly; John M Haynes; Mark Williamson; Neeranat Thienthong; David J Owen; Christopher J H Porter
Journal:  J Control Release       Date:  2014-03-14       Impact factor: 9.776

Review 3.  Recent advances in controlled pulmonary drug delivery.

Authors:  Zhenglin Liang; Rui Ni; Jieyu Zhou; Shirui Mao
Journal:  Drug Discov Today       Date:  2014-10-02       Impact factor: 7.851

4.  Co-Spray Dried Mannitol/Poly(amidoamine)-Doxorubicin Dry-Powder Inhaler Formulations for Lung Adenocarcinoma: Morphology, In Vitro Evaluation, and Aerodynamic Performance.

Authors:  Qian Zhong
Journal:  AAPS PharmSciTech       Date:  2017-08-23       Impact factor: 3.246

5.  Synthesis and characterisation of mucoadhesive thiolated polymers.

Authors:  A Bernkop-Schnürch; S Steininger
Journal:  Int J Pharm       Date:  2000-01-25       Impact factor: 5.875

6.  Pulmonary delivery of growth hormone using dry powders and visualization of its local fate in rats.

Authors:  Cynthia Bosquillon; Véronique Préat; Rita Vanbever
Journal:  J Control Release       Date:  2004-04-28       Impact factor: 9.776

7.  Conjugation to Poly(amidoamine) Dendrimers and Pulmonary Delivery Reduce Cardiac Accumulation and Enhance Antitumor Activity of Doxorubicin in Lung Metastasis.

Authors:  Qian Zhong; Elizabeth R Bielski; Leonan S Rodrigues; Matthew R Brown; Joshua J Reineke; Sandro R P da Rocha
Journal:  Mol Pharm       Date:  2016-06-10       Impact factor: 4.939

8.  Insulin-loaded PLGA/cyclodextrin large porous particles with improved aerosolization properties: in vivo deposition and hypoglycaemic activity after delivery to rat lungs.

Authors:  Francesca Ungaro; Roberta d'Emmanuele di Villa Bianca; Concetta Giovino; Agnese Miro; Raffaella Sorrentino; Fabiana Quaglia; Maria Immacolata La Rotonda
Journal:  J Control Release       Date:  2008-12-25       Impact factor: 9.776

9.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

Review 10.  Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles.

Authors:  Günter Oberdörster; Eva Oberdörster; Jan Oberdörster
Journal:  Environ Health Perspect       Date:  2005-07       Impact factor: 9.031

View more
  4 in total

1.  Poloxamer 407 and Hyaluronic Acid Thermosensitive Hydrogel-Encapsulated Ginsenoside Rg3 to Promote Skin Wound Healing.

Authors:  Xiaojuan Peng; Chuanbo Ding; Yingchun Zhao; Mingqian Hao; Wencong Liu; Min Yang; Fengyan Xiao; Yinan Zheng
Journal:  Front Bioeng Biotechnol       Date:  2022-07-05

Review 2.  Ginsenosides emerging as both bifunctional drugs and nanocarriers for enhanced antitumor therapies.

Authors:  Hong Wang; Yu Zheng; Qiang Sun; Zhen Zhang; Mengnan Zhao; Cheng Peng; Sanjun Shi
Journal:  J Nanobiotechnology       Date:  2021-10-15       Impact factor: 10.435

Review 3.  Preparation and pharmacological effects of minor ginsenoside nanoparticles: a review.

Authors:  Yue Ke; Lei Huang; Yu Song; Zhenxin Liu; Linshuang Liang; Linmao Wang; Taoyun Wang
Journal:  Front Pharmacol       Date:  2022-08-08       Impact factor: 5.988

4.  In Vitro and In Vivo Inhibitory Effect of Gujin Xiaoliu Tang in Non-Small Cell Lung Cancer.

Authors:  Chao Hou; Dai-Han Zhou; Yong-Jian Wu; Xiao-Jun Dai; Qing-Ying Wang; Yin-Qiu Wu; En-Xin Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2018-09-09       Impact factor: 2.629

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.